Wingo Aliza P, Vattathil Selina M, Liu Jiaqi, Fan Wen, Cutler David J, Levey Allan I, Schneider Julie A, Bennett David A, Wingo Thomas S
Division of Mental Health, Atlanta VA Medical Center, Decatur, Georgia, USA.
Department of Psychiatry, Emory University School of Medicine, Atlanta, Georgia, USA.
J Neurol Neurosurg Psychiatry. 2022 Jun 30;93(9):930-8. doi: 10.1136/jnnp-2021-328164.
is a strong risk factor for Alzheimer's disease (AD) and associated with higher low-density lipoprotein cholesterol (LDL-C) levels. Moreover, LDL-C is associated with the development of clinically ascertained AD; however, whether this association is present with the underlying neuropathological manifestations of AD or whether it is independent of the effect of is unknown and is the focus of this paper.
Individuals in the Religious Orders Study/Memory and Ageing Project cohorts with longitudinal measures of blood lipids and detailed autopsies were studied. We modelled the relationship between blood lipids and 12 age-related brain pathologies using a linear mixed model adjusted for potential confounding factors and stratified by genotype with overall significance determined by meta-analysis. Blood lipids considered were LDL-C, high-density lipoprotein cholesterol and triglycerides. Brain pathologies included AD pathology measured by silver staining (Braak stage, a modified Consortium to Establish a Registry for Alzheimer's Disease [CERAD] score and global AD pathology) and immunohistochemistry (beta-amyloid and neurofibrillary tangles) as well as cerebral microinfarct, cerebral macroinfarct, cerebral amyloid angiopathy, cerebral atherosclerosis, hippocampal sclerosis, TDP-43 cytoplasmic inclusions and Lewy bodies.
559 participants (69.1% female) had complete data for analysis. They were followed for a median of 7 years and a median of 3 years prior to dementia onset. LDL-C was associated with all measures of AD neuropathology (neurofibrillary tangles, beta-amyloid, Braak stage, modified CERAD score and global AD pathology) and cerebral amyloid angiopathy independent of after adjusting for age, sex, cholesterol-lowering medication use, body mass index, smoking and education at false discovery rate (FDR) p-value <0.05.
These findings implicate LDL-C in the pathophysiology of AD independent of and suggest LDL-C is a modifiable risk factor for AD.
是阿尔茨海默病(AD)的一个强风险因素,且与较高的低密度脂蛋白胆固醇(LDL-C)水平相关。此外,LDL-C与临床确诊的AD的发生有关;然而,这种关联是否存在于AD的潜在神经病理学表现中,或者它是否独立于的影响尚不清楚,这也是本文的重点。
对宗教秩序研究/记忆与衰老项目队列中具有血脂纵向测量数据和详细尸检的个体进行了研究。我们使用线性混合模型对血脂与12种与年龄相关的脑病理学之间的关系进行建模,该模型针对潜在混杂因素进行了调整,并按基因型分层,通过荟萃分析确定总体显著性。所考虑的血脂包括LDL-C、高密度脂蛋白胆固醇和甘油三酯。脑病理学包括通过银染色测量的AD病理学(Braak分期、改良的阿尔茨海默病注册协会[CERAD]评分和总体AD病理学)以及免疫组织化学(β-淀粉样蛋白和神经原纤维缠结),以及脑微梗死、脑大梗死、脑淀粉样血管病、脑动脉粥样硬化、海马硬化、TDP-43细胞质包涵体和路易体。
559名参与者(69.1%为女性)有完整的数据用于分析。他们在痴呆症发病前的中位随访时间为7年,中位观察时间为3年。在调整年龄、性别、降脂药物使用、体重指数、吸烟和教育程度后,LDL-C与AD神经病理学的所有测量指标(神经原纤维缠结、β-淀粉样蛋白、Braak分期、改良CERAD评分和总体AD病理学)以及脑淀粉样血管病独立相关,错误发现率(FDR)p值<0.05。
这些发现表明LDL-C在AD的病理生理学中独立于,提示LDL-C是AD的一个可改变的风险因素。